Targeted Therapies for Castration-Resistant Prostate Cancer

The past decade has witnessed the remarkable development of new, highly effective approaches for the treatment of advanced prostate cancer – new hormonal agents, cytotoxic chemotherapeutic drugs, targeted therapeutics and immunotherapy. This book thoroughly reviews the current

state of systemic therapy for prostate cancer, including agents approved or undergoing investigation, building on

the intensive research of the past three decades that has elucidated the specific molecular mechanisms by which the prostate cancer cell achieves castration resistance.


This timely collection of chapters from internationally recognized experts covers all the significant advances in the field. The emphasis in each chapter is on the mechanism of action of the agents, and the authors take pains to describe precisely their response rates, impact on survival and adverse effects.



Chapter list

Castration-resistant prostate cancer: Peter Scardino

Overview of disease pathways and drug targets: Himisha Beltran & Scott T

Tagawa

Antiangiogenesis agents: David E Adelberg & William L Dahut

Bone stroma inhibition: Michael A Carducci & Daniel Keizman

Hormone treatment for prostate cancer: Janusz Mezynski & Johann De Bono

Immunotherapy for prostate cancer: Cinzia Remondo & James L Gulley

Insulin-like growth factor receptor type 1 as a target for cancer therapy: Liliane

Goetsch, Véronique Caussanel & Nathalie Corvaïa

Chemotherapy for castration-resistant prostate cancer: Guru Sonpavde & Cora

N Sternberg

CTLA-4 inhibitors in castration-resistant prostate cancer: Sumit K Subudhi,

Howard I Scher & James P Allisonr